drugset / Trial / NCT03483324
Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation
Phase 1
Completed
10 enrolled
Angiocrine Bioscience
California Institute for Regenerative Medicine (CIRM) · collab
NaSingle-groupOpen-labelTreatment
Summary
A phase 1b, open label, multi-center trial of AB-110 in adults with hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia (MDS) undergoing cord blood transplantation. Subjects will receive unmanipulated cord blood (UCB) and AB-110 expanded CD34 enriched hematopoietic progenitor cells (HSPC).
Timeline
- Start
- 2018-04-24
- Primary completion
- 2020-12-21
- Completion
- 2022-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AB-110 | Cell therapy | — | — |
| Background | Unmanipulated Umbilical Cord Blood (UCB) | Cell therapy | — | — |